Novo Nordisk also announced that it has filed regulatory applications seeking approval for the oral version of Wegovy (25mg) for the treatment of obesity. Novo Nordisk is the first company to seek ...

Lars Fruergaard Jørgensen, the boss of Danish pharmaceutical giant Novo Nordisk, explained what impact the drugs can have on users weight in the long run ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Avery is known for songs such as 'Go Screw Yourself (GSY) and 'Meant to Live', but the artist took to social media earlier ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention. Helen Coffey speaks to the dentists warning that jabs could have a worrying im ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk needs the facilities to help ramp up production of key growth medicines, including semaglutide-based Ozempic for diabetes and Wegovy for obesity, which have seen their growth held ...